Cargando…
Management of hemostasis and coagulopathies for surgical and critically ill patients : an evidence-based approach /
Management of Hemostasis and Coagulopathies for Surgical and Critically Ill Patients: An Evidence-Based Approach offers a concise guide to a sub-specialty of transfusion medicine from the clinical laboratory perspective. It focuses on the clinical tests that may be done during preoperative assessmen...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores principales: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam, Netherlands :
Elsevier,
[2016]
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Management of Hemostasis and Coagulopathies for Surgical and Critically Ill Patients; Copyright Page; Contents; Preface; 1 Coagulation-Based Tests and Their Interpretation; 1.1 Introduction; 1.2 Complete Blood Count; 1.3 Tests for Platelet Function; 1.3.1 PFA-100; 1.3.2 VerifyNow; 1.3.3 Plateletworks; 1.3.4 Platelet Aggregation; 1.4 Prothrombin Time; 1.5 Partial Thromboplastin Time; 1.6 Thrombin Time; 1.7 Fibrinogen Level; 1.7.1 D-Dimer; 1.7.2 Antithrombin III Level; 1.7.3 Mixing Study; 1.8 Thromboelastography; 1.8.1 Platelet Mapping; 1.8.2 Anti-Xa Assay.
- 1.8.3 Plasma-Diluted Thrombin Time1.9 Heparin-Induced Thrombocytopenia; 1.9.1 Bleeding Patient With Normal Coagulation Tests; 1.10 Conclusions; References; 2 Blood Bank Testing and Blood Products; 2.1 Introduction; 2.2 Blood Collection and Testings; 2.2.1 ABO/Rh(D) Typing; 2.2.2 Antibody Screen; 2.2.3 Antibody Identification by Extended (Panel) Testing; 2.2.4 Implications of the Presence of Antibodies; 2.2.5 Crossmatch; 2.3 Blood Components; 2.3.1 Whole Blood; 2.3.2 Packed Red Blood Cells; 2.3.3 Fresh Frozen Plasma; 2.3.4 Plasma Variants; 2.3.5 Platelets; 2.3.6 Cryoprecipitate.
- 2.4 Release of Blood Products2.4.1 Autologous Blood; 2.4.2 Transfusion Reactions; 2.4.3 Transfusion-Related Acute Lung Injury; 2.4.4 Transfusion-Related Graft-Versus-Host Disease; 2.5 Transfusion Reaction Workup; 2.5.1 RhIg; 2.6 Conclusions; References; 3 Pharmacotherapy With Antiplatelet, Anticoagulant, and Their Reversing Agents; 3.1 Introduction; 3.2 Antiplatelet and Anticoagulant Agents: An Overview; 3.3 Reversing Agents: An Overview; 3.4 Aspirin; 3.4.1 Monitoring Aspirin Therapy; 3.5 Adenosine Diphosphate Receptor Blockers; 3.5.1 Ticlopidine and Clopidogrel; 3.5.2 Prasugrel.
- 3.5.3 Ticagrelor3.5.4 Cangrelor; 3.5.4.1 Monitoring Therapy with ADP Receptor-Blocking Agents; 3.6 Glycoprotein IIB/IIIA Inhibitors; 3.7 Phosphodiesterase Inhibitors; 3.8 Thrombin Receptor Antagonist; 3.9 Warfarin; 3.9.1 Reversal of Warfarin Therapy; 3.10 Heparin and Low-Molecular-Weight Heparin; 3.10.1 Low-Molecular-Weight Heparin; 3.10.2 Reversible Agents for Heparin; 3.11 Direct Thrombin Inhibitors; 3.11.1 Parenterally Administered Direct Thrombin Inhibitors; 3.11.2 Orally Administered Direct Thrombin Inhibitors; 3.12 Factor XA Inhibitors; 3.13 Conclusions; References.
- 4 Antiplatelets and Anticoagulants4.1 Introduction; 4.2 Monitoring and Reversal for Coumadin; 4.2.1 Reversal of Coumadin With Supratherapeutic INR; 4.3 Monitoring and Reversal for Unfractionated Heparin; 4.3.1 Reversal of UFH; 4.4 Monitoring and Reversal for Bivalirudin (Angiomax); 4.5 Monitoring and Reversal for Dabigatran; 4.6 Monitoring and Reversal for Rivaroxaban (Xarelto) and Apixaban; 4.7 Monitoring for Aspirin and P2Y12 Platelet Inhibitors; 4.8 Bridging Anticoagulants for Surgery; 4.9 Conclusions; References; 5 Preoperative Assessment of Patients; 5.1 Introduction; 5.2 History.